Stock EFTR EFFECTOR THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages eFFECTOR Therapeutics, Inc.

Equities

EFTR

US28202V2079

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
1.6 USD -5.88% Intraday chart for eFFECTOR Therapeutics, Inc. -10.11% -86.31%
May. 20 EFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer CI
May. 09 EFFECTOR Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
EFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer
EFFECTOR Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Health Care Down on Retreat From Risk -- Health Care Roundup
Top Midday Decliners
EFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer
EFFECTOR Therapeutics, Inc. Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer
Top Premarket Decliners
EFFECTOR Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
Transcript : EFFECTOR Therapeutics, Inc. - Special Call
EFFECTOR Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
EFFECTOR Therapeutics Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Transcript : EFFECTOR Therapeutics, Inc. - Special Call
EFFECTOR Therapeutics to Host Virtual Investor R&D Day on January 24, 2024
EFFECTOR Therapeutics to Host Virtual Investor R&D Day on January 24, 2024
EFFECTOR Therapeutics Announces Reverse Stock Split
EFFECTOR Therapeutics Announces Reverse Stock Split
EFFECTOR THERAPEUTICS ANNOUNCES NEW POSITIVE INTERIM DATA FROM DOSE ESCALATION AND PHASE 2 EXPANSION COHORTS OF ZOTATIFIN IN ER+ METASTATIC BREAST CANCER PATIENTS
EFFECTOR Therapeutics Says Study of Zotatifin in Breast Cancer Patients Yields 'Positive' Interim Data
EFFECTOR Therapeutics Announces New Positive Interim Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in ER+ Metastatic Breast Cancer Patients
EFFECTOR Therapeutics Announces New Positive Interim Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in ER+ Metastatic Breast Cancer Patients
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. EFTR Stock
  4. News eFFECTOR Therapeutics, Inc.
  5. Other languages